BeiGene Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

BeiGene şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.2%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: B1GN34 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: B1GN34 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

BeiGene Piyasaya Karşı Temettü Getirisi

B1GN34 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (B1GN34)	n/a
Pazarın Alt %25'i (BR)	3.0%
Pazarın En İyi %25'i (BR)	9.5%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (B1GN34) (3 yıla kadar)	0%

Önemli Temettü: B1GN34 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, B1GN34 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: B1GN34 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: B1GN34 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

BeiGene Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee

BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024

BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. Announces CFO Changes

BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd., Annual General Meeting, Jun 05, 2024

BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024

BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib)

Beigene, Ltd. Announces Board Changes

BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC

BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R)

Beigene, Ltd. Announces Change of Chair of Audit Committee

Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC

Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication

BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023

BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma

Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Beigene, Ltd. Provides Update Regarding Recent Business Developments

BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma in Great Britain by MHRA

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Products Administration Accepts Supplemental Biologics License Application

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica (Ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker At ASH

Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for Brukinsa® Versus Imbruvica® in Late-Breaking Oral Session At Ash 2022

Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee

BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (Cll)

Beigene, Ltd. Announces Brazil Approvals for Brukinsa® as A Treatment for Rare Blood Cancers

Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment in Phase II Clinical Trial for Investigational Pan-FGFR Inhibitor ABSK091 in Combination with Anti-PD-1 Antibody Tislelizumab Developed by BeiGene, Ltd. in Urothelial Carcinoma

BeiGene Receives European Commission Approval for BRUKINSA(R) (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BeiGene, Ltd. Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL

Beigene Announces Positive Topline Results from Final Progression-Free Survival Analysis of Brukinsa® (Zanubrutinib) Compared to Imbruvica® (Ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (Cll) Trial

NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström’s Macroglobulinemia Who Have Had At Least One Treatment

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin